HighTower Advisors’s Marker Therapeutics MRKR Stock Holding History

HighTower Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,208	Closed	-$6K	–	3574
2022 Q4	$6K	Buy	2,208 +500	+29%	+$1.73K	﹤0.01%	3201
2022 Q3	$6K	Hold	1,708	–	–	﹤0.01%	3045
2022 Q2	$6K	Hold	1,708	–	–	﹤0.01%	3108
2022 Q1	$7K	Hold	1,708	–	–	﹤0.01%	3241
2021 Q4	$16K	Hold	1,708	–	–	﹤0.01%	3127
2021 Q3	$29K	Sell	1,708 -10	-0.6%	-$205	﹤0.01%	2982
2021 Q2	$47K	Hold	1,718	–	–	﹤0.01%	2899
2021 Q1	$38K	Buy	+1,718	New	+$39.3K	﹤0.01%	2859

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's MRKR Position: Q1 2023 in Review

HighTower Advisors sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 2,208 shares — an estimated $6K sold.

HighTower Advisors first reported a position in MRKR in Q1 2021 and held it in 8 quarters. The position peaked at $47K in Q2 2021. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

HighTower Advisors reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 2,208 Marker Therapeutics shares in Q1 2023, an estimated $6K.
HighTower Advisors first reported a position in Marker Therapeutics in Q1 2021 and held it in 8 quarters.
HighTower Advisors's Marker Therapeutics position peaked at $47K in Q2 2021.
30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.